Drug Profile
Research programme: anti-TNF monoclonal antibodies - Arana Therapeutics
Alternative Names: Anti-TNF monoclonal antibodies research programme - Arana Therapeutics; PN 0615Latest Information Update: 02 Mar 2011
Price :
$50
*
At a glance
- Originator Peptech
- Class Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 21 Aug 2009 This programme is in active development
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 19 Apr 2005 Preclinical trials in Rheumatoid arthritis in Australia (Injection)